CNN’s Meg Tirrell gets to the heart of the matter in “The end of a shortage of popular weight-loss...
How Misunderstanding Compounded Drugs Puts Patients at Risk
Compounded medications save lives. They fill critical gaps when commercial drugs are unavailable or inappropriate. Yet, far too often, they’re misunderstood — and misrepresented — by the media, regulators, and even the pharmaceutical industry.
In a recent DC Journal op-ed, APC CEO Scott Brunner calls for greater truth and clarity in how compounded drugs are discussed. He examines the real harm caused by labeling these medications as “knockoffs,” “copycats,” or “unapproved,” and explains how conflating them with counterfeit drugs undermines trust in a vital part of modern healthcare.
What’s at Stake:
Language matters. Sensational labels may grab attention, but they distort the facts and diminish the integrity of licensed pharmacists.
"Unapproved" ≠ Unsafe. Compounded medications are not mass-produced, so they aren’t FDA-approved — but they are legal, regulated, and essential to care.
Compounding ≠ Counterfeiting. These are not the same — and confusing them can endanger patient safety.
Real-world impact. From pediatric sickle cell treatments to hospital drug shortages, compounded medications are often the only option available to those in need.
Brunner’s article is a compelling reminder that the way we talk about compounded medications shapes public perception, impacts policy, and most importantly — affects patient care.
